Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 Pathway  





2 Pathology  





3 References  





4 Further references  














Polyol pathway






Français

Српски / srpski
Türkçe
 

Edit links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


The polyol pathway is a two-step process that converts glucose to fructose.[1] In this pathway glucose is reduced to sorbitol, which is subsequently oxidized to fructose. It is also called the sorbitol-aldose reductase pathway.

The pathway is implicated in diabetic complications, especially in microvascular damage to the retina,[2] kidney,[3] and nerves.[4]

Sorbitol cannot cross cell membranes, and, when it accumulates, it produces osmotic stresses on cells by drawing water into the insulin-independent tissues.[5]

Pathway[edit]

The polyol metabolic pathway.[6]

Cells use glucose for energy. This normally occurs by phosphorylation from the enzyme hexokinase. However, if large amounts of glucose are present (as in diabetes mellitus), hexokinase becomes saturated and the excess glucose enters the polyol pathway when aldose reductase reduces it to sorbitol. This reaction oxidizes NADPHtoNADP+. Sorbitol dehydrogenase can then oxidize sorbitol to fructose, which produces NADH from NAD+. Hexokinase can return the molecule to the glycolysis pathway by phosphorylating fructose to form fructose-6-phosphate. However, in uncontrolled diabetics that have high blood glucose - more than the glycolysis pathway can handle - the reactions mass balance ultimately favors the production of sorbitol.[6]

Activation of the polyol pathway results in a decrease of reduced NADPH and oxidized NAD+; these are necessary co-factors in redox reactions throughout the body, and under normal conditions they are not interchangeable. The decreased concentration of these NADPH leads to decreased synthesis of reduced glutathione, nitric oxide, myo-inositol, and taurine. Myo-inositol is particularly required for the normal function of nerves. Sorbitol may also glycate nitrogens on proteins, such as collagen, and the products of these glycations are referred-to as AGEs - advanced glycation end-products. AGEs are thought to cause disease in the human body, one effect of which is mediated by RAGE (receptor for advanced glycation end-products) and the ensuing inflammatory responses induced. They are seen in the hemoglobin A1C tests performed on known diabetics to assess their levels of glucose control.[6]

Pathology[edit]

While most cells require the action of insulin for glucose to gain entry into the cell, the cells of the retina, kidney, and nervous tissues are insulin-independent, so glucose moves freely across the cell membrane, regardless of the action of insulin. The cells will use glucose for energy as normal, and any glucose not used for energy will enter the polyol pathway. When blood glucose is normal (about 100 mg/dL or 5.5 mmol/L), this interchange causes no problems, as aldose reductase has a low affinity for glucose at normal concentrations.[citation needed]

In a hyperglycemic state, the affinity of aldose reductase for glucose rises, causing much sorbitol to accumulate, and using much more NADPH, leaving less NADPH for other processes of cellular metabolism.[7] This change of affinity is what is meant by activation of the pathway. The amount of sorbitol that accumulates, however, may not be sufficient to cause osmotic influx of water.

NADPH acts to promote nitric oxide production and glutathione reduction, and its deficiency will cause glutathione deficiency. A glutathione deficiency, congenital or acquired, can lead to hemolysis caused by oxidative stress. Nitric oxide is one of the important vasodilators in blood vessels. Therefore, NADPH prevents reactive oxygen species from accumulating and damaging cells.[6]

Excessive activation of the polyol pathway increases intracellular and extracellular sorbitol concentrations, increased concentrations of reactive oxygen species, and decreased concentrations of nitric oxide and glutathione. Each of these imbalances can damage cells; in diabetes there are several acting together. It has not been conclusively determined that activating the polyol pathway damages the microvascular systems.[6]

References[edit]

  1. ^ Bonnefont-Rousselot D (September 2002). "Glucose and reactive oxygen species". Current Opinion in Clinical Nutrition and Metabolic Care. 5 (5): 561–8. doi:10.1097/00075197-200209000-00016. PMID 12172481. S2CID 20485164.
  • ^ Behl T, Kaur I, Kotwani A (2016). "Implication of oxidative stress in progression of diabetic retinopathy". Survey of Ophthalmology. 61 (2): 187–96. doi:10.1016/j.survophthal.2015.06.001. PMID 26074354.
  • ^ Forbes JM, Coughlan MT, Cooper ME (June 2008). "Oxidative stress as a major culprit in kidney disease in diabetes". Diabetes. 57 (6): 1446–54. doi:10.2337/db08-0057. PMID 18511445.
  • ^ Javed S, Petropoulos IN, Alam U, Malik RA (January 2015). "Treatment of painful diabetic neuropathy". Therapeutic Advances in Chronic Disease. 6 (1): 15–28. doi:10.1177/2040622314552071. PMC 4269610. PMID 25553239.
  • ^ Jedziniak JA, Chylack LT, Cheng HM, Gillis MK, Kalustian AA, Tung WH (March 1981). "The sorbitol pathway in the human lens: aldose reductase and polyol dehydrogenase". Investigative Ophthalmology & Visual Science. 20 (3): 314–26. PMID 6782033.
  • ^ a b c d e Michael Brownlee (2005). "The pathobiology of diabetic complications: A unifying mechanism". Diabetes. 54 (6): 1615–1625. doi:10.2337/diabetes.54.6.1615. PMID 15919781.
  • ^ Brownlee M (December 2001). "Biochemistry and molecular cell biology of diabetic complications". Nature. 414 (6865): 813–20. Bibcode:2001Natur.414..813B. doi:10.1038/414813a. PMID 11742414. S2CID 4396508.
  • Further references[edit]


    Retrieved from "https://en.wikipedia.org/w/index.php?title=Polyol_pathway&oldid=1187568811"

    Categories: 
    Chemical pathology
    Metabolic pathways
    Diabetes
    Hidden categories: 
    Articles with short description
    Short description matches Wikidata
    All articles with unsourced statements
    Articles with unsourced statements from November 2023
     



    This page was last edited on 30 November 2023, at 01:38 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki